Erratum: Two-year outcome of an observe-andplan regimen for neovascular agerelated macular degeneration: How to alleviate the clinical burden with maintained functional results (Eye (2015) 29 (342-349) DOI: 10.1038/eye.2014.258);Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: How to alleviate the clinical burden with maintained functional results

Eye (Basingstoke)

Volumn 29, Issue 3, 2015, Pages 342-349

  Gianniou, C ^a   Dirani, A ^a   Ferrini, W ^a   Marchionno, L ^a   Decugis, D ^a   Deli, A ^a   Ambresin, A ^a   Mantel, I ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PATIENT MONITORING; PROSPECTIVE STUDY; READING; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME FACTOR; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RANIBIZUMAB; RECURRENCE; RETREATMENT; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84924907143     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.321     Document Type: Erratum

References (28)

1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82(11): 844-851.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444.
3. Brown DM,Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116(1): 57-65.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431.
5. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six- week results of the VIEW studies. Ophthalmology 2014; 121(1): 193-201.
6. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119(12): 2537-2548.
7. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153(2): 209-213 e202.
8. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010; 150(3): 315-324.
9. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145(2): 239-248.
10. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, xer-Siegel R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118(5): 831-839.
11. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z et al. Twelve-month efficacy and safety of 0.5mg or 2.0mg ranibizumab in patients with subfoveal neovascular agerelated macular degeneration. Ophthalmology 2013; 120(5): 1046-1056.
12. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-1908.
13. Han DP. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice? JAMA Ophthalmol 2013; 131(9): 1124-1126
14. Mantel I, Niderprim SA, Gianniou C, Deli A, Ambresin A. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol 2014; 98(9): 1192-1196.
15. Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013; 251(3): 697-704.
16. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119(7): 1399-1411.
17. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
18. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117(11): 2134-2140.
19. Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology 2013; 120(5 Suppl): S3-S7.
20. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148(1): 43-58.
21. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118(4): 663-671.
22. Tschuor P, Pilly B, Venugopal D, Gale RP. Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. Graefes Arch Clin Exp Ophthalmol 2013; 251(10): 2327-2330.
23. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 2014; 252(4): 647-655.
24. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009; 116(9): 1740-1747.
25. Gerding H. [Treatment of wet AMD with less than 12 injections of Ranibizumab per year]. Klin Monatsbl Augenheilkd 2010; 227(4): 294-297.
26. Gerding H. Ranibizumab treatment in age-related macular degeneration: a meta-analysis of one-year results. Klin Monatsbl Augenheilkd 2014; 231(4): 427-431.
27. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular agerelated macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014; 121(5): 1092-1101.
28. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011; 118(3): 523-530.